Ifebemtinib
Star0
Identification
- Generic Name
- Ifebemtinib
- DrugBank Accession Number
- DB17570
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 588.564
Monoisotopic: 588.210816058 - Chemical Formula
- C28H28F4N6O4
- Synonyms
- Ifebemtinib
- External IDs
- BI 853520
- BI-853520
- BI853520
- IN 10018
- IN-10018
- IN10018
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C57O858DKU
- CAS number
- 1227948-82-4
- InChI Key
- ULMMVBPTWVRPSI-UHFFFAOYSA-N
- InChI
- InChI=1S/C28H28F4N6O4/c1-37-9-7-16(8-10-37)34-24(39)17-11-22(41-3)20(12-19(17)29)35-27-33-13-18(28(30,31)32)25(36-27)42-21-6-4-5-15-14-38(2)26(40)23(15)21/h4-6,11-13,16H,7-10,14H2,1-3H3,(H,34,39)(H,33,35,36)
- IUPAC Name
- 2-fluoro-5-methoxy-4-({4-[(2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-N-(1-methylpiperidin-4-yl)benzamide
- SMILES
- COC1=C(NC2=NC=C(C(OC3=CC=CC4=C3C(=O)N(C)C4)=N2)C(F)(F)F)C=C(F)C(=C1)C(=O)NC1CCN(C)CC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 58951583
- BindingDB
- 134067
- ChEMBL
- CHEMBL3657311
- ZINC
- ZINC000138456718
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Recurrent Ovarian Cancer 1 1 Completed Treatment Gastric Cancer 1 1 Completed Treatment Neoplasm 2 1 Recruiting Treatment Metastatic Melanoma 1 1, 2 Active Not Recruiting Treatment Locally Advanced or Metastatic Solid Tumor(s) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 3.28 Chemaxon pKa (Strongest Acidic) 10.84 Chemaxon pKa (Strongest Basic) 8.5 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 108.92 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 147.21 m3·mol-1 Chemaxon Polarizability 57.46 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at March 01, 2023 20:13 / Updated at March 03, 2023 17:28